LINEZOLID INJECTION 2 MG
LINEZOLID : 2 MG · DIN 02430827 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is LINEZOLID INJECTION?
LINEZOLID INJECTION 2 MG contains LINEZOLID : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02430827, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 12-Jun-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LINEZOLID INJECTION used for?
Adults: Vancomycin-Resistant Enterococcus faecium (VREF); Nosocomial pneumonia; Community-acquired pneumonia; Complicated skin and skin structure infections (including diabetic foot infections).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02430827 |
|---|---|
| Brand name | LINEZOLID INJECTION |
| Generic / active ingredient | LINEZOLID : 2 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 2 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01XX08 LINEZOLID |
| AHFS class | 08:12.28.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Jun-2015 |
| Original market date | 2015-06-12 00:00:00 |
How is it administered?
600 mg intravenous every 12 hours (q12h). Infusion over 30 to 120 minutes. Duration typically 10 to 28 days depending on infection type.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Supplied as a ready-to-use sterile isotonic solution. (Specific temperature range not explicitly stated in provided text, but noted as ready-to-use).
How is it supplied?
Single-use, ready-to-use flexible plastic infusion bags (PVC-free, DEHP-free) in a foil laminate overwrap. 600 mg linezolid in 300 mL of solution per bag.
Contraindications
Hypersensitivity to linezolid; use of MAO inhibitors within 2 weeks; uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome unless monitored for BP/serotonin syndrome.
Warnings and precautions
Myelosuppression (monitor CBC weekly); Lactic acidosis; Serotonin syndrome; Peripheral/optic neuropathy (long-term use); CDAD; Hyponatremia; Rhabdomyolysis. Not for Gram-negative infections.
Is LINEZOLID in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01XX08 LINEZOLID. 8 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LINEZOLID | 600 MG | TABLET | APOTEX INC | MARKETED | DIN 02426552 |
| JAMP LINEZOLID | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02520354 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02539748 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02481278 |
| SANDOZ LINEZOLID | 600 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02422689 |
| ZYVOXAM | 100 MG / 5 ML | POWDER FOR SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02243686 |
| ZYVOXAM | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02243685 |
| LINEZOLID | 600 MG | TABLET | PANDA PHARMACEUTICALS INC. | CANCELLED PRE MARKET | DIN 02457903 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02429527 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02402637 |
Who else supplies LINEZOLID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LINEZOLID appears in 784 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.